Clinical impacts of tumor cell contamination of hematopoietic stem cell products in metastatic breast cancer patients undergoing autologous peripheral blood stem cell transplantation: Multicenter trial

Citation
Mj. Ahn et al., Clinical impacts of tumor cell contamination of hematopoietic stem cell products in metastatic breast cancer patients undergoing autologous peripheral blood stem cell transplantation: Multicenter trial, J KOR MED S, 16(2), 2001, pp. 175-182
Citations number
37
Language
INGLESE
art.tipo
Article
Categorie Soggetti
General & Internal Medicine
Journal title
JOURNAL OF KOREAN MEDICAL SCIENCE
ISSN journal
1011-8934 → ACNP
Volume
16
Issue
2
Year of publication
2001
Pages
175 - 182
Database
ISI
SICI code
1011-8934(200104)16:2<175:CIOTCC>2.0.ZU;2-U
Abstract
To determine whether the tumor cell contamination of peripheral blood stem cells influences clinical impacts on high-dose chemotherapy in patients wit h metastatic breast cancer, we analyzed carcinoembryonic antigen (CEA) mRNA in the apheresis products by nested RT-PCR (reverse transcriptase-polymera se drain reaction). A total of 38 metastatic breast cancer patients and ten normal healthy subjects as a negative control were included. Twenty out of 38 (51.3%) apheresis products from patients with metastatic breast cancer were positive for CEA mRNA. CEA mRNA was noted in 54.8% (17/31) of patients mobilized with chemotherapy plus G-CSF and 42.8% (3/7) of patients with G- CSF alone. There was no significant difference in age, estrogen receptor, m enopausal status, mobilization method, disease free interval, or number of metastasis sites (1 vs greater than or equal to2) between positive and nega tive groups. The presence of CEA mRNA in apheresis products did not influen ce the time to progression and overall survival in both groups. However, bo th the univariate and the multivariate analysis disclosed that the number o f metastasis was associated with survival significantly. We suggest that th e tumor cell contamination does not predict poor treatment outcome in patie nts with metastatic breast cancer.